London · 15–19 November 2026
London Life Sciences Week Guide
Explore Onyx’s independent guide to the events and make the most of your week in London.
Archive
The Onyx record. Explore every story, from the latest development to the earliest dispatch.
All stories
We’ve made a London Life Sciences Week Guide
NewsGranza Bio pairs T-cell ‘attack particles’ with CAR-T in a single targeted particle, CEO says at Meeting on the Mesa
NewsOrca Bio CEO says Tregzi launch hinges on getting manufacturing right every time, at Meeting on the Mesa
NewsOri Biotech weighs moving some manufacturing to China, CEO tells Meeting on the Mesa panel
NewsTenaya Therapeutics to update on pivotal plans for heart gene therapies by year end, CEO says at Meeting on the Mesa
NewsKyverna on track to complete miv-cel filing in stiff person syndrome this quarter, CEO says at Meeting on the Mesa
NewsRoche licenses Rona's ALK7 RNAi obesity candidate in deal worth up to $1.16 billion
NewsAspect Biosystems plans clinical data in 2027 from cell therapy pipeline, CEO says at Meeting on the Mesa
NewsSartorius says one operator can run eight cell therapy patients on Eveo platform at Meeting on the Mesa
NewsCGT Catapult pitches ‘federation’ to lower cell and gene therapy development costs at Meeting on the Mesa
NewsBOOST Pharma outlines placebo-controlled trial of up to 80 patients for brittle bone cell therapy BT-101 at Meeting on the Mesa
NewsARM’s Tim Hunt says the FDA ‘has stabilized’ and points to seven more blockbusters at Meeting on the Mesa
NewsFDA’s CBER director says US will ‘never’ have China- or Australia-style system, wants one rare disease package
NewsRocket Pharmaceuticals explains lower dose behind Danon gene therapy restart at Meeting on the Mesa
NewsArbor Biotechnologies sets out CNS gene editing push with three ALS candidates at Meeting on the Mesa
NewsME Therapeutics' Salim Dhanji on making the patient's body the bioreactor
Exclusive InterviewsCreasallis' Zahra Jawad on why US investors said yes before Cambridge did
Exclusive InterviewsThe primal blueprint: how CamMed mimics evolution to reinvent self-amplifying RNA
Exclusive InterviewsFDA approves GSK's Jideytro for ROS1-positive lung cancer, a week after the Nuvalent acquisition closed
FDA GreenlitFDA Grants Orphan Drug Designation to Affinia Therapeutics' AFTX-201 for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)
Press ReleaseClene Nanomedicine's ALS drug is a gold nanocrystal you drink. It missed its primary endpoint. The FDA is still listening.
Exclusive InterviewsFDA approves Merck's Lipfendra, a once-daily oral PCSK9 inhibitor for lowering LDL cholesterol
FDA GreenlitFDA approves Celcuity's Revtorpyk for PIK3CA wild-type breast cancer after CDK4/6 failure
FDA GreenlitFDA grants Vera's Trutakna accelerated approval to reduce proteinuria in IgA nephropathy
FDA GreenlitFDA approvals - June 2026
FDA GreenlitFDA approves Viridian's Lumvoa for thyroid eye disease in both active and chronic disease
FDA GreenlitFDA approves GSK's Utebzi, an oral antibiotic for complicated urinary tract infections with few alternatives
FDA GreenlitFDA approves Bayer's Ambelvist, an MRI contrast agent with a lower gadolinium dose
FDA GreenlitKim Brown, CEO, Compass Biomedical | Onyx Live | ISCT Dublin 2026
Live InterviewsJason Jones, Head of Global Business Development, Cellular Origins | Onyx Live | ISCT Dublin 2026
Live InterviewsDimitrios Kouroupis, Professor, University of Miami | Onyx Live | ISCT Dublin 2026
Live InterviewsJon Ellis, CEO, Trenchant BioSystems | Onyx Live | ISCT Dublin 2026
Live InterviewsSean Werner, CTO, BioLife Solutions | Onyx Live | ISCT Dublin 2026
Live InterviewsAugustin de Bettignies, Chief Business Officer, MPC Therapeutics | Onyx Live | ISCT Dublin 2026
Live InterviewsFDA approvals - May 2026
FDA GreenlitStephen Sullivan, Founder & Managing Director, Lindville Bio | Onyx Live | ISCT Dublin 2026
Live InterviewsJeff Galecke, Managing Partner, i5 BioPartners | Onyx Live | ISCT Dublin 2026
Live InterviewsSven Kili, Partner, Saisei Ventures | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsBruce Levine, Co-inventor of Kymriah, University of Pennsylvania | Onyx Live | ISCT Dublin 2026
Live InterviewsMiguel Forte, President, ISCT | Onyx Live | ISCT Dublin 2026
Live InterviewsFDA approves Shionogi's Xocova, an oral antiviral for preventing COVID-19 after exposure
FDA GreenlitFDA approves Wockhardt's Zaynich, an intravenous antibiotic for complicated urinary tract infections
FDA GreenlitLisa Deschamps, CEO, AviadoBio | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsMarion Hitchcock, Managing Director, Gene & Cell Therapies Incubator Berlin | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsFaraz Ali, CEO, Tenaya Therapeutics | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsFDA approves AbbVie's Decnupaz, a CD123-directed antibody-drug conjugate, for blastic plasmacytoid dendritic cell neoplasm
FDA GreenlitFDA approves Gilead's Hepcludex as the first treatment for chronic hepatitis delta
FDA GreenlitBernd Mühlenweg, CBO/CFO, Cellbox Solutions | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsSarmitha Sathiamoorthy, President & Founder, AspireBio Consulting | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsAlberto Santagostino, CEO & President, AGC Biologics | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsAli Soleymannezhad, Chief Commercial Officer, Cellares | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsFather Kevin FitzGerald, Professor of Medical Humanities, Creighton University | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsSteffen Thirstrup, Chief Medical Officer, European Medicines Agency | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsJosh Schroeder, Chief of Staff, CTI Clinical Trial and Consulting Services | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsDevyn Smith, CEO, Arbor Biotechnologies | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsAlexander Seyf, CEO, Autolomous | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsVictor Levitsky, CSO, Circio Holding ASA | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsLawrence Tallon, CEO, Medicines and Healthcare products Regulatory Agency | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsFDA approves AstraZeneca's Baxfendy, an aldosterone synthase inhibitor for uncontrolled hypertension
FDA GreenliteSpraye (Pulmonary fibrosis, Dry Powder) - Onyx Analyst
Onyx ExplainsFDA grants BeOne's Beqalzi accelerated approval in mantle cell lymphoma after a BTK inhibitor
FDA GreenlitStephen Majors, Vice President, Global Communications and Investor Relations, Alliance for Regenerative Medicine | Onyx Live | Cell & Gene Meeting on the Med 2026
Live InterviewsFDA approves Arvinas and Pfizer's Veppanu, a PROTAC protein degrader, in ESR1-mutated breast cancer
FDA GreenlitEric Schlumpf, President & CEO, Stuart Therapeutics | Onyx Live | JPM 2026
Live InterviewsStuart Lowe, Head of Advanced Therapies, TTP | Onyx Live | Advanced Therapies 2026
Live InterviewsThe sugar layer biotech forgot - and why Anomer Bio thinks small molecules can finally drug it
Biotech & Life SciencesStuart Curbishley, Chief Development & Manufacturing Officer, adthera bio | Onyx Live | Advanced Therapies 2026
Live InterviewsMiguel Forte, President, International Society for Cell & Gene Therapy | Onyx Live | Advanced Therapies 2026
Live InterviewsAffinia Therapeutics to Present AFTX-201 for BAG3-Associated Dilated Cardiomyopathy (DCM) and Highlight Proprietary Capsid Engineering and Manufacturing Data at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Press ReleaseDemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)
Press ReleaseFDA approves Merck's Idvynso, a doravirine and islatravir tablet, four years after a clinical hold on islatravir
FDA GreenlitAlexander Seyf, CEO, Autolomous | Onyx Live | Advanced Therapies 2026
Live InterviewsMarinna Madrid, Co-Founder, Cellino | Onyx Live | JPM 2026
Live InterviewsAffinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)
Press ReleaseFDA approvals - March 2026
Biotech & Life SciencesNovartis to acquire Excellergy, adding Phase 1 anti-IgE program
Biotech & Life SciencesNovo Nordisk's Awiqli delivers the first once-weekly basal insulin for type 2 diabetes
FDA GreenlitFDA approves Rocket's Kresladi as the first gene therapy for severe leukocyte adhesion deficiency-I
FDA GreenlitAspect Biosystems Announces $280 Million Partnership with Government of Canada to Advance Development of Bioengineered Cellular Medicines
Press ReleaseBrad Sitko, CIO, XOMA Royalty | Onyx Live | JPM 2026
Live InterviewsAvi Veidman, CEO, Nucleai | Onyx Live | JPM 2026
Live InterviewsMerck to Acquire Terns, Adding TERN-701 to Hematology Pipeline
Biotech & Life SciencesKali licenses KT501 to Sanofi in autoimmune disease deal
Biotech & Life SciencesDenali’s AVLAYAH wins FDA accelerated approval in Hunter syndrome
Biotech & Life SciencesFDA formally refuses to approve Vanda's tradipitant for gastroparesis after protracted regulatory battle
FDA GreenlitREGENXBIO's Hunter syndrome gene therapy RGX-121 receives CRL as FDA questions trial design and biomarker endpoint
FDA GreenlitFDA Clears Corcept’s Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
Biotech & Life SciencesWill biotech still be relevant in 2030? | Treehill Partners Ep. 3 | JPM 2026
Live InterviewsIndia semaglutide market sees new moves from Lupin, Zydus, and Sun Pharma
Biotech & Life SciencesFDA expands IMCIVREE label to acquired hypothalamic obesity as EMANATE misses primary endpoints
Biotech & Life SciencesAbbott completes Exact Sciences deal, expanding diagnostics portfolio in cancer screening
Biotech & Life SciencesPaul Denslow, CEO, Intus Bio | Onyx Live | JPM 2026
Live InterviewsOryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s Disease
Press ReleaseOryon Cell Therapies Emerges From Stealth Focusing on Autologous Neuron Replacement Therapies for Parkinson’s Disease and Other Neurodegenerative Disorders
Press ReleaseMike Cordonnier, CEO, Carlsmed | Onyx Live | JPM 2026
Live InterviewsAldeyra receives FDA complete response letter for Reproxalap
Biotech & Life SciencesJohnson & Johnson’s ICOTYDE brings a new oral IL-23 option to plaque psoriasis
Biotech & Life SciencesFDA approves Alfasigma’s Lynavoy for primary biliary cholangitis
Biotech & Life SciencesAdditional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS
Press ReleaseNovartis expands Cosentyx label with FDA approval in adolescent Hidradenitis Suppurativa
Biotech & Life Sciences